Intermittent high-dose intravenous interferon alfa-2b for adjuvant treatment of stage III melanoma: Final analysis of a randomized phase III dermatologic cooperative oncology group trial

Journal of Clinical Oncology

Volumn 33, Issue 34, 2015, Pages 4077-4084

  Mohr, Peter ^a   Hauschild, Axel ^b   Trefzer, Uwe ^c   Enk, Alexander ^d   Tilgen, Wolfgang ^e   Loquai, Carmen ^f   Gogas, Helen ^r   Haalck, Thomas ^g   Koller, Josef ^s   Dummer, Reinhard ^t   Gutzmer, Ralf ^h   Brockmeyer, Norbert ⁱ   Hölzle, Erhard ^j   Sunderkötter, Cord ^k   Mauch, Cornelia ^l   Stein, Annette ^m   Schneider, Lars A ⁿ   Podda, Maurizio ^o   Göppner, Daniela ^p   Schadendorf, Dirk ^q   Weichenthal, Michael ^b   more..

^a Am Krankenhaus 1   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ RUHR UNIVERSITY BOCHUM   (Germany)

^j KLINIKUM OLDENBURG   (Germany)

^k UNIVERSITY OF MÜNSTER   (Germany)

^l UNIVERSITY OF COLOGNE   (Germany)

^m UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁿ UNIVERSITY OF ULM   (Germany)

^o Darmstadt Hospital   (Germany)

^p UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^q UNIVERSITY HOSPITAL ESSEN   (Germany)

^r Hellenic Cooperative Oncology Group   (Greece)

^s PARACELSUS MEDICAL UNIVERSITY   (Austria)

^t UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CREATINE KINASE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISTANT METASTASIS FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; IN-TRANSIT METASTASIS; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LIVER TOXICITY; LYMPH NODE DISSECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MOOD DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SIDE EFFECT; STANDARD; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SKIN NEOPLASMS; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOMBINANT PROTEINS; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84951727237     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.6932     Document Type: Article

References (24)

1. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
2. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High-And low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000
3. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
4. Eggermont AM, Suciu S, Testori A, et al: Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48:218-225, 2012
5. Eggermont AM, Suciu S, Santinami M, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet 372:117-126, 2008
6. Grob JJ, Dreno B, de la Salmoniere P, et al: Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 351:1905-1910, 1998
7. Pehamberger H, Soyer HP, Steiner A, et al: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 16:1425-1429, 1998
8. Cascinelli N, Belli F, MacKie RM, et al: Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 358:866-869, 2001
9. Hancock BW, Wheatley K, Harris S, et al: Adjuvant interferon in high-risk melanoma: The AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22:53-61, 2004
10. Garbe C, Radny P, Linse R, et al: Adjuvant low-dose interferon alpha 2a with or without dacarbazine compared with surgery alone: A prospectiverandomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 19:1195-1201, 2008
11. Hauschild A, Kahler KC, Schafer M, et al: Interdisciplinary management recommendations for toxicity associated with interferon-Alfa therapy. J Dtsch Dermatol Ges 6:829-37:829-838, 2008
12. Kirkwood JM, Bender C, Agarwala S, et al: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20:3703-3718, 2002
13. Pectasides D, Dafni U, Bafaloukos D, et al: Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 27:939-944, 2009
14. Payne MJ, Argyropoulou K, Lorigan P, et al: Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol 32:185-190, 2014
15. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
16. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
17. Agarwala SS, Lee SJ, Flaherty LE, et al: Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate-And high-risk melanoma (Intergroup Trial E 1697). J Clin Oncol 29:527s, 2011 (abstr 8505)
18. Mao L, Si L, Chi Z, et al: A randomised phase II trial of 1 month versus 1 year of adjuvant highdose interferon alpha-2b in high-risk acral melanoma patients. Eur J Cancer 47:1498-1503, 2011
19. Chiarion-Sileni V, Guida M, Romanini A, et al: Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial-ISRCTN75125874. J Clin Oncol 29:527s, 2011 (abstr 8506)
20. Nashan D, Reuter K, Mohr P, et al: Understanding and managing interferon-Alpha-related fatigue in patients with melanoma. Melanoma Res 22:415-423, 2012
21. Chiarion-Sileni V, Del Bianco P, Romanini A, et al: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: A randomized phase III Italian Melanoma Inter-group trial (IMI-Mel.A)- ISRCTN75125874. BMC Cancer 6:44, 2006
22. Rubin KM, Vona K, Madden K, et al: Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: A nurse's perspective. Support Care Cancer 20:1601-1611, 2012
23. Levesque N, Mitchinson K, Lawrie D, et al: Health management program: Factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma. Curr Oncol 15:36-41, 2008
24. Kilbridge KL, Weeks JC, Sober AJ, et al: Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 19:812-823, 2001